Please ensure Javascript is enabled for purposes of website accessibility

Vir Biotechnology and Alnylam Pick a Coronavirus Antiviral Candidate to Pursue

By Cory Renauer – Updated May 4, 2020 at 2:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The partners will develop VIR-2703, which has the potential to prevent COVID-19, and also to treat it.

The collaboration between Vir Biotechnology (VIR 7.66%) and Alnylam (ALNY 2.26%) that they expanded in March to address COVID-19 has selected a treatment candidate to advance into clinical trials. The partners will seek accelerated approval from regulators to treat human volunteers with VIR-2703, also known as ALN-COV, which makes it hard for the SARS-CoV-2 coronavirus to reproduce. 

The partners selected their candidate from hundreds of small interfering RNA (siRNA) strands that targeted different portions of the SARS-CoV-2 genome. The partners still aren't sure if they want to develop VIR-2703 as a treatment for patients with COVID-19 or as an antiviral to prevent its transmission, but they do know that in the laboratory, it inhibits the production of the virus responsible for COVID-19 at relatively low concentrations. Vir and Alnylam plan to develop VIR-2703 as an inhaled formula.

Pipetting samples in a laboratory.

Image source: Getty Images.

Unfortunately, the encouraging results that they have reported so far are only the first steps in the marathon process of  developing a new drug. And regulators usually want to see safety results from lots of lengthy animal studies before they allow investigators to treat people with a new molecular entity.

The development timeline for VIR-2703 is a little fuzzy because the partners still haven't had formal discussions with any regulators about an accelerated path for advancing it into human studies. They intend to meet with the FDA soon to discuss a plan that could allow clinical trials to begin by the end of 2020.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
$201.24 (2.26%) $4.45
Vir Biotechnology, Inc. Stock Quote
Vir Biotechnology, Inc.
$21.49 (7.66%) $1.53

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.